Literature DB >> 15889979

Angiogenic therapy for coronary artery and peripheral arterial disease.

G Chad Hughes1, Brian H Annex.   

Abstract

Neovascularization in chronically ischemic adult cardiac and skeletal muscle results from the processes of angiogenesis, arteriogenesis and vasculogenesis. Therapeutic angiogenesis describes an emerging field of cardiovascular medicine whereby new blood vessels are induced to grow to supply oxygen and nutrients to cardiac or skeletal muscle rendered ischemic as a result of progressive atherosclerosis. Various techniques have been utilized to promote new blood vessel growth in the heart and extremities, including mechanical means such as surgical or percutaneous myocardial laser revascularization, angiogenic growth factor therapies involving members of the vascular endothelial growth factor and fibroblast growth factor families, and more recently, cellular-based therapies using stem cells known as endothelial progenitor cells or angioblasts. The following review discusses each of these treatment strategies in detail including both preclinical and clinical data for their use in peripheral arterial and coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15889979     DOI: 10.1586/14779072.3.3.521

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  10 in total

Review 1.  Systems biology of pro-angiogenic therapies targeting the VEGF system.

Authors:  Feilim Mac Gabhann; Amina A Qutub; Brian H Annex; Aleksander S Popel
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2010 Nov-Dec

2.  Reducible poly(amido ethylenediamine) for hypoxia-inducible VEGF delivery.

Authors:  Lane V Christensen; Chien-Wen Chang; James W Yockman; Rafe Conners; Heidi Jackson; Zhiyuan Zhong; Jan Feijen; David A Bull; Sung Wan Kim
Journal:  J Control Release       Date:  2006-12-28       Impact factor: 9.776

Review 3.  Spatiotemporal control over growth factor signaling for therapeutic neovascularization.

Authors:  Lan Cao; David J Mooney
Journal:  Adv Drug Deliv Rev       Date:  2007-08-16       Impact factor: 15.470

Review 4.  Microvascular repair: post-angiogenesis vascular dynamics.

Authors:  Amanda J LeBlanc; Laxminarayanan Krishnan; Christopher J Sullivan; Stuart K Williams; James B Hoying
Journal:  Microcirculation       Date:  2012-11       Impact factor: 2.628

5.  Simvastatin augments the efficacy of therapeutic angiogenesis induced by bone marrow-derived mesenchymal stem cells in a murine model of hindlimb ischemia.

Authors:  Yuqing Zhang; Rusheng Zhang; Yong Li; Guoping He; Dingguo Zhang; Fumin Zhang
Journal:  Mol Biol Rep       Date:  2011-05-07       Impact factor: 2.316

6.  Angiotensin type I receptor blockade in conjunction with enhanced Akt activation restores coronary collateral growth in the metabolic syndrome.

Authors:  Rashmi Jadhav; Tracy Dodd; Erika Smith; Erin Bailey; Angelo L Delucia; James C Russell; Rowan Madison; Barry Potter; Kenneth Walsh; Hanjoong Jo; Petra Rocic
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-02-18       Impact factor: 4.733

7.  Plasma chemokine levels are associated with the presence and extent of angiographic coronary collaterals in chronic ischemic heart disease.

Authors:  Ellen C Keeley; J Randall Moorman; Ling Liu; Lawrence W Gimple; Lewis C Lipson; Michael Ragosta; Angela M Taylor; Douglas E Lake; Marie D Burdick; Borna Mehrad; Robert M Strieter
Journal:  PLoS One       Date:  2011-06-22       Impact factor: 3.240

8.  Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial.

Authors:  Vesa Anttila; Antti Saraste; Juhani Knuuti; Pekka Jaakkola; Marja Hedman; Sara Svedlund; Maria Lagerström-Fermér; Magnus Kjaer; Anders Jeppsson; Li-Ming Gan
Journal:  Mol Ther Methods Clin Dev       Date:  2020-06-01       Impact factor: 6.698

Review 9.  From bench to bedside: review of gene and cell-based therapies and the slow advancement into phase 3 clinical trials, with a focus on Aastrom's Ixmyelocel-T.

Authors:  Ronnda L Bartel; Erin Booth; Caryn Cramer; Kelly Ledford; Sharon Watling; Frank Zeigler
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

10.  VEGFR1 promotes cell migration and proliferation through PLCγ and PI3K pathways.

Authors:  Jared C Weddell; Si Chen; P I Imoukhuede
Journal:  NPJ Syst Biol Appl       Date:  2017-12-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.